Counselors in Meguon, WI Accepting Medicare
1 Counselors found. Showing 1 - 1
 Mr. Ronald John Gammon, CADCIII CCS Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: North Shore Center, 10303 N Port Washington Rd Sq 203, Meguon, WI 53092 Phone: 262-241-5955 Fax: 262-241-5926 |
News Archive
Lawmakers step in on airport X ray radiation exposure issue
In a bid to protect passengers from radiation exposure, members of Congress are calling on the Transportation Security Administration (TSA) to release inspection reports that would show whether airport X-ray machines that screen passengers and bags are meeting requirements to emit only low levels of radiation. There have been doubts in the recent past that the X-ray machines are not properly monitored and maintained and when the TSA refused to clarify, the lawmakers have stepped in.
Living with a COVID-19 case brings worse symptoms and stronger antibody response
This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.
Oxfam says 'no evidence' AMFm has saved lives; Global Fund says claims are 'untrue,' Guardian reports
Noting "the U.K. government has contributed £70 million [$112 million] to the Affordable Medicines Facility for malaria (AMFm)," the Guardian reports, "The charity Oxfam has cast doubt on the international scheme that aims to boost the provision of the most effective treatment for malaria."
Researchers investigate whether aspirin can decrease rate of intracranial aneurysm growth
Researchers conducted a database search to investigate whether aspirin can aid in the prevention of intracranial aneurysm rupture by hindering aneurysm growth. The researchers identified 146 patients harboring multiple intracranial aneurysms, five millimeters or less in diameter, that had been observed for at least five years.
Ipsen grants license to Debiopharm for developing and commercialising cancer treatment
Ipsen (Euronext:IPN), an innovation-driven global specialty pharmaceutical Group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced today the signature of an agreement under which Debiopharm is granted an exclusive worldwide license to develop and commercialise Ipsen's first-in-class inhibitor of the CDC25 phosphatase enzyme (now Debio 0931), for the treatment of various human cancers.
› Verified 8 days ago